Valuation: ThermoGenesis Holdings, Inc.

Capitalization 11.09K 9.54K 8.93K 8.33K 15.38K 998K 16.73K 104K 40.34K 472K 41.63K 40.75K 1.72M P/E ratio 2022
-0.16x
P/E ratio 2023 -0.08x
Enterprise value 9.29M 7.99M 7.48M 6.98M 12.88M 836M 14.01M 87.53M 33.8M 395M 34.88M 34.13M 1.44B EV / Sales 2022
0.97x
EV / Sales 2023 1.18x
Free-Float
71.98%
Yield 2022 *
-
Yield 2023 -
More valuation ratios * Estimated data
Dynamic Chart
1 week 0
Extreme 0.0001
0
1 month 0
Extreme 0.0001
0
Current year 0
Extreme 0
0
1 year 0
Extreme 0
0.01
3 years 0
Extreme 0
6.67
5 years 0
Extreme 0
200.25
10 years 0
Extreme 0
3,600
More quotes
Manager TitleAgeSince
Chief Executive Officer 54 02/11/2016
Investor Relations Contact - -
Director TitleAgeSince
Chairman 54 02/11/2016
Director/Board Member - 13/07/2023
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
0.00%0.00%-80.00%-100.00% 1.58K
-0.56%-4.19%+12.48%-2.68% 28.9B
-0.41%-1.12%+3.84%+7.27% 8.2B
+0.31%-.--%-.--%+21.47% 3.25B
+4.97%+0.53%+31.19% - 2.59B
0.00%-3.40%-36.09%-66.51% 2.11B
+0.76%+4.48%-6.51%+18.29% 1.66B
+2.61%+1.82%+4.74%+6.89% 1.54B
+1.58%-3.42%+24.82%+64.24% 1.1B
+0.67%-5.06%+10.57%+95.99% 1.06B
Average +0.99%-1.65%-3.50%+5.00% 5.04B
Weighted average by Cap. +0.04%-2.91%+8.56%+2.62%
See all sector performances

Financials

2022 2023
Net sales 10.48M 9.01M 8.44M 7.87M 14.53M 943M 15.81M 98.74M 38.12M 446M 39.34M 38.51M 1.63B 9.44M 8.12M 7.61M 7.09M 13.09M 850M 14.24M 88.96M 34.35M 401M 35.45M 34.69M 1.47B
Net income -11.27M -9.69M -9.08M -8.46M -15.62M -1.01B -16.99M -106M -40.99M -479M -42.3M -41.4M -1.75B -17.98M -15.45M -14.47M -13.49M -24.92M -1.62B -27.1M -169M -65.37M -764M -67.46M -66.02M -2.79B
Net Debt 6.89M 5.92M 5.55M 5.17M 9.55M 620M 10.39M 64.88M 25.05M 293M 25.85M 25.3M 1.07B 9.28M 7.98M 7.47M 6.97M 12.87M 835M 14M 87.43M 33.76M 395M 34.84M 34.09M 1.44B
More financial data * Estimated data
Logo ThermoGenesis Holdings, Inc.
ThermoGenesis Holdings, Inc. develops and commercializes a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics. The Company provides the AutoXpress and BioArchive platforms for automated clinical bio-banking, the PXP platform for point-of-care cell-based therapies and X-Series products for cell processing services. Its product lines include Clinical Bio-Banking Applications, Point-of-Care Applications and Cell Processing. Its Clinical Bio-Banking Applications include AXP II Automated Cell Separation System and BioArchive Automated Cryopreservation System. Its Point-of-Care Applications include PXP Point-of-Care System, and PXP-1000 System. Its Cell Processing includes X-Series Products for general laboratory use: X-Lab for cell isolation, X-Wash System for cell washing and reformulation, and X-Mini for high efficiency small scale cell purification. The Company markets and sells its medical device products through independent distributors.
Employees
25
More about the company
Date Price Change Volume

Delayed Quote OTC Markets, December 04, 2025 at 07:28 pm

More quotes

Quarterly revenue - Rate of surprise